US Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market to Grow at a CAGR of 7.2% to reach US$ 733.71 million from 2022 to 2030
市场洞察和分析师观点:
荧光原位杂交 (FISH) 是一种用于细胞遗传学分析的分子技术。该技术使用仅与具有高度序列互补性的核酸序列的特定部分结合的荧光探针。 FISH 可检测染色体上是否存在特定 DNA 序列。 FISH 通常用于寻找 DNA/RNA 靶点的特定特征,用于医学、遗传咨询和物种鉴定。推动荧光原位杂交(FISH)成像系统市场增长的关键因素包括目标疾病患病率的上升以及体外诊断研发投资的增加。然而,FISH 成像系统和程序的高成本阻碍了市场增长。
增长驱动因素和限制:
FISH 是一种强大的分子细胞遗传学技术,可实现细胞或组织内特定 DNA 序列的可视化和定位。这项技术彻底改变了遗传学和诊断领域,为研究人员和临床医生提供了有关遗传异常、染色体重排和各种疾病的宝贵见解。遗传综合征、癌症和其他遗传异常等目标疾病的患病率不断增加,推动了对 FISH 成像系统的需求。根据国家医学图书馆的数据,预计 2023 年美国将新增 1.96 例癌症病例和 609,820 例癌症死亡病例。随着这些目标疾病患病率的持续上升,对准确可靠的诊断工具的需求激增。 FISH 成像系统提供高分辨率图像,帮助检测细微的基因变化,从而实现早期疾病诊断和个性化治疗方法。这些疾病通常涉及基因突变或变异,可以使用 FISH 成像系统准确识别和表征。事实证明,精确绘制细胞内特定基因或 DNA 序列位置的能力对于了解疾病机制、开发靶向疗法和做出明智的临床决策至关重要。
FISH 的一个显着优势在于其能够处理各种样本类型,包括福尔马林固定石蜡包埋组织、细胞学制剂和新鲜组织。这种多功能性使 FISH 成为研究和临床环境中的重要工具,可以识别与白血病、淋巴瘤、实体瘤和先天性疾病等疾病相关的遗传标记。
荧光原位杂交 (FISH) 成像系统市场受到对体外诊断 (IVD) 相关研发 (R&D) 活动的持续投资的进一步推动。凭借其在细胞环境中可视化特定 DNA 序列的独特能力,FISH 技术已成为现代诊断的关键程序,特别是在检测遗传性疾病和罕见疾病方面。 IVD 研发资金的激增促进了 FISH 成像系统的变革性进步,研究人员能够创建尖端平台,提供增强的图像质量和支持简化自动化的功能,最终实现更准确、更快速的诊断过程。 PNA FISH 是一种使用 FISH 结合肽核酸 (PNA) 探针的新型诊断方法,将传统染色程序的简便性与 PNA 探针的卓越性能相结合,可快速、准确地诊断传染病,这使得 PNA FISH 适合常规检测使临床微生物学实验室能够在使用传统生化方法无法实现的时间范围内报告患者治疗的重要信息。
然而,FISH 成像分析由于其成本相对较高,因此在癌症检测中不太常用。其他方法。除了设备成本之外,与试剂、其他消耗品和专业人员任命相关的费用也会增加基于 FISH 成像的评估的总体成本。例如,在美国,通过 IHC 检测 ALK 基因非小细胞肺癌的每次检测费用为 90.07 美元,低于 FISH 和 IHC 的独立或平行检测(美国的费用约为 441.85 美元) 。因此,程序和系统的高成本限制了荧光原位杂交 (FISH) 成像系统市场的增长。
报告细分和范围:
“美国荧光原位杂交 (FISH) 成像系统” FISH)成像系统市场”根据产品、应用和最终用户进行细分。根据产品,市场分为仪器、消耗品、配件和软件。从应用来看,荧光原位杂交(FISH)成像系统市场分为癌症诊断、遗传病诊断、传染病诊断等。根据最终用户,市场分为诊断实验室、合同研究组织、制药和生物技术公司等。
细分分析:
美国荧光原位杂交 (FISH) 成像系统市场(按产品) ,分为仪器、消耗品、配件和软件。消耗品领域在 2022 年占据最大的市场份额,预计 2022 年至 2030 年复合年增长率最高。耗材是荧光原位杂交 (FISH) 成像系统市场中最有前途的部分,将在未来几年带来巨大的增长。 FISH耗材包括杂交缓冲液、探针、标签检测试剂盒、信号放大检测试剂盒等。 Abbott、F. Abnova 和 Thermo Fisher Scientific 等制造商的存在增强了耗材领域的市场。这些产品经常用于各种研究诊断过程,预计将推动消费。因此,提供探针和试剂盒的各种市场参与者的存在以及市场参与者的技术进步可能会在未来几年推动该细分市场的市场。
荧光原位杂交 (FISH) 成像系统市场(按产品) – 2022年和2030年
根据应用,荧光原位杂交(FISH)成像系统市场细分为癌症诊断、遗传病诊断、传染病诊断等。癌症诊断领域在 2022 年占据最大的市场份额,预计 2022 年至 2030 年复合年增长率最高。 FISH 技术极大地有益于癌症诊断。 FISH 成像系统可以寻找基因变化并帮助检测异常。据英国癌症研究中心称,FISH 检测可用于诊断多种癌症,包括乳腺癌、淋巴瘤、肺癌、前列腺癌、慢性淋巴细胞白血病 (CLL)、急性淋巴细胞白血病 (ALL)、急性髓性白血病 (AML)、慢性粒细胞白血病 (CML)、骨髓瘤、尤文氏肉瘤和黑色素瘤皮肤癌。
根据最终用户,荧光原位杂交 (FISH) 成像系统市场分为诊断实验室、合同研究组织、制药和生物技术公司等。诊断实验室细分市场在 2022 年占据最大的市场份额,预计 2022 年至 2030 年复合年增长率最高。诊断实验室参与各种研究项目,开发用于荧光原位杂交 (FISH) 成像过程的多种技术和产品。研究和技术的空前发展为医疗保健和生命科学领域的转型创造了潜力。荧光原位杂交(FISH)成像系统的临床应用非常广泛,为提高慢性病的诊断和治疗能力提供了机会。它们在基因发现和罕见遗传疾病的诊断方面具有巨大的潜力。这些技术越来越多地用于分析影响癌症、高血压、糖尿病和肾脏疾病等常见疾病发展的罕见和常见遗传因素。
荧光原位杂交 (FISH) 成像系统市场机会:< br>由于技术进步的激增,FISH 成像系统正在经历显着的发展,从而带来改变基因研究和诊断格局的尖端创新。这些进步包括增强的光学、更灵敏和多功能的荧光团以及复杂的自动化功能。现代 FISH 成像系统集成了这些升级功能,可提供更高的灵敏度、更高的图像分辨率和更快的处理时间。此外,这些技术进步将FISH成像的应用范围从癌症诊断扩展到遗传倾向检测。 2023 年 4 月,安捷伦科技公司与 PathAI 建立了合作伙伴关系。此次合作使安捷伦和 PathAI 能够构建包含检测和机器学习分析算法的集成解决方案。同样,2023 年 5 月,辉瑞和赛默飞世尔科技公司签订了一项合作协议,帮助拉丁美洲、非洲、中东和非洲等 30 多个国家的肺癌和乳腺癌患者在本地获得基于下一代测序 (NGS) 的检测。中东和亚洲的先进基因组测试以前有限或不可用。获得本地 NGS 测试有助于更快地分析相关基因,从而使医疗保健提供者能够为特定患者选择最佳药物。因此,FISH 成像系统的技术进步为荧光原位杂交 (FISH) 成像系统市场的公司创造了重大机会。
国家分析:
据估计,美国拥有最大的荧光原位杂交 (FISH) 成像系统市场。 )预测期内成像系统的市场份额。对分子遗传学和细胞遗传学先进诊断工具的需求不断增长,以及遗传性疾病和癌症患病率的上升,推动了荧光原位杂交 (FISH) 成像系统在美国的采用。根据美国癌症协会2022年公布的数据,美国诊断出近190万癌症病例,报告癌症死亡人数为609,360人。这些系统提供遗传物质的高分辨率成像,使研究人员和临床医生能够更准确地检测染色体异常和基因突变。此外,对个性化医疗和靶向治疗的日益关注导致涉及遗传分析的研究活动激增,从而增加了对 FISH 成像系统的需求。这些系统直接提供细胞内基因序列详细空间信息的能力已被证明在研究和临床应用中具有无价的价值。 FISH 成像系统最近因其技术进步(例如改进的自动化、更高的吞吐量和增强的图像分析软件)而广受欢迎。因此,实验室和医疗机构能够更好地处理大量样本并有效生成精确的结果。因此,分子遗传学和细胞遗传学领域对先进诊断工具的需求不断增长,以及遗传性疾病和癌症患病率的上升,推动了美国荧光原位杂交 (FISH) 成像系统市场的发展。
行业发展和未来机遇:< br>美国荧光原位杂交 (FISH) 成像系统市场的主要参与者采取的各种举措如下:
2023 年 5 月,辉瑞和赛默飞世尔科技公司合作,帮助增加本地获得下一代技术的机会为拉丁美洲、非洲、中东和亚洲 30 多个国家的肺癌和乳腺癌患者提供基于测序 (NGS) 的检测,这些国家的高级基因组检测以前受到限制或不可用。获得本地 NGS 测试有助于更快地分析相关基因,从而使医疗保健提供者能够为特定患者选择最佳药物。 2023 年 4 月,安捷伦科技公司与韩国 Theragen Bio 签署了一份谅解备忘录。作为合作协议的一部分,安捷伦和 Theragen Bio 结合了各自在癌症基因组分析设计、工程知识和软件专业知识方面的优势,以推动本地化分析能力并加速治疗决策。 2023 年 1 月,全球服务领导者 Thermo Fisher Scientific Inc science 已完成从 Nordic Capital 领导的股东集团手中收购全球领先的专业诊断公司 The Binding Site Group,交易金额为 23 亿英镑(按当前汇率计算为 28 亿美元),全现金交易。 Binding Site 为现有的专业诊断产品组合增添了多发性骨髓瘤诊断和监测方面的开创性创新。早期检测和明智的治疗决策可以极大地影响患者的治疗结果。2021 年 12 月,BioGenex Laboratories Inc 推出了三种用于癌症诊断的新型初级免疫组织化学 (IHC) 抗体——CD8A、CD56 和 CD163。2021 年 4 月,应用光谱成像 (ASI) 和KromaTiD Inc 已建立战略商业合作伙伴关系,允许 ASI 在全球范围内销售 KromaTiD 专有的 Pinpoint FISH (PPF) 探针和检测服务。竞争格局和主要公司:
Euroclone SpA、TissueGnostics GmbH、Agilent Technologies Inc、Abnova Taiwan Corp、 BioGenex Laboratories Inc、Leica Biosystems Nussloch GmbH、MetaSystems Probes GmbH、Bio-View Ltd、Thermo Fisher Scientific Inc、Applied Spectral Imaging 和 PerkinElmer Inc 是荧光原位杂交 (FISH) 成像系统市场的知名参与者。这些公司专注于新技术、现有产品的进步和地域扩张,以满足全球不断增长的消费者需求并增加其专业产品组合的产品范围。
![Report Coverage](https://www.theinsightpartners.com/assets/rdimages/report_coverage.png)
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
![Segment Covered](https://www.theinsightpartners.com/assets/rdimages/segment_covered.png)
Segment Covered
This text is related
to segments covered.
![Regional Scope](https://www.theinsightpartners.com/assets/rdimages/regional_scope.png)
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
![Country Scope](https://www.theinsightpartners.com/assets/rdimages/country_scope.png)
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Fluorescence in situ hybridization (FISH) is a molecular technique for cytogenetic analysis. This technique uses fluorescent probes that bind to only particular parts of a nucleic acid sequence with a high degree of sequence complementarity. FISH detects the presence or absence of specific DNA sequences on chromosomes. FISH is often used to find specific features in DNA/RNA targets for medicine, genetic counseling, and species identification.
Factors such as the rising prevalence of target disorders and the increasing R&D investments in in-vitro diagnostics propel market growth.
The fluorescence in-situ hybridization (FISH) imaging systems market majorly consists of the players, including Euroclone SpA, TissueGnostics GmbH, Agilent Technologies Inc, Abnova Taiwan Corp, BioGenex Laboratories Inc, Leica Biosystems Nussloch GmbH, MetaSystems Probes GmbH, Bio-View Ltd, Thermo Fisher Scientific Inc, Applied Spectral Imaging, and PerkinElmer Inc.
The fluorescence in-situ hybridization (FISH) imaging systems market was valued at US$ 419.74 million in 2022.
The fluorescence in-situ hybridization (FISH) imaging systems market, by end user, is segmented into diagnostic laboratories, contract research organizations, pharmaceutical and biotechnological companies, and others. The diagnostic laboratories segment held a larger market share in 2022, and the same segment is anticipated to register a higher CAGR.
The fluorescence in-situ hybridization (FISH) imaging systems market is expected to be valued at US$ 733.71 million in 2030.
The US fluorescence in-situ hybridization (FISH) imaging systems market, by application, is segmented into cancer diagnosis, genetic disease diagnosis, infectious disease diagnosis, and others. The cancer diagnosis segment held a larger market share in 2022, and the same segment is anticipated to register a higher CAGR.
The fluorescence in-situ hybridization (FISH) imaging systems market, by services, is segmented into pharmacokinetics, biomarkers, immunogenicity, virology testing, cell-based assays, and others. The cell-based assays segment held a larger market share in 2022. Also, the same segment is anticipated to register a higher CAGR.
The List of Companies - U.S. Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market
- Euroclone SpA
- TissueGnostics GmbH
- Agilent Technologies Inc
- Abnova Taiwan Corp
- BioGenex Laboratories Inc
- Leica Biosystems Nussloch GmbH
- MetaSystems Probes GmbH
- Bio-View Ltd
- Thermo Fisher Scientific Inc
- Applied Spectral Imaging
- PerkinElmer Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.